Circulating endothelial progenitor cell: a promising biomarker in clinical oncology
详细信息 查看全文
- 作者：Yu-Zheng Ge (1)
Ran Wu (1)
Tian-Ze Lu (1)
Hui Xin (1)
Peng Yu (2)
Yan Zhao (3)
Hao Liu (4)
Zheng Xu (1)
Lu-Wei Xu (1)
Jiang-Wei Shen (1)
Xiao Xu (5)
Liu-Hua Zhou (1)
Wen-Cheng Li (1)
Jia-Geng Zhu (1)
Rui-Peng Jia (1) - 关键词：Endothelial progenitor cells ; Cancer ; Vascularization ; Biomarker
- 刊名：Medical Oncology
- 出版年：2015
- 出版时间：January 2015
- 年：2015
- 卷：32
- 期：1
- 全文大小：242 KB
- 参考文献：1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9鈥?9. CrossRef
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57鈥?0. CrossRef
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646鈥?4. CrossRef
4. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298鈥?07. CrossRef
5. Liu J, Huang J, Yao WY, Ben QW, Chen DF, He XY, et al. The origins of vacularization in tumors. Front Biosci (Landmark Ed). 2012;17:2559鈥?5. CrossRef
6. Hardee ME, Zagzag D. Mechanisms of glioma-associated neovascularization. Am J Pathol. 2012;181(4):1126鈥?1. CrossRef
7. Asahara T, Kawamoto A. Endothelial progenitor cells for postnatal vasculogenesis. Am J Physiol Cell Physiol. 2004;287(3):C572鈥?. CrossRef
8. Patenaude A, Parker J, Karsan A. Involvement of endothelial progenitor cells in tumor vascularization. Microvasc Res. 2010;79(3):217鈥?3. CrossRef
9. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275(5302):964鈥?. CrossRef
10. Ding YT, Kumar S, Yu DC. The role of endothelial progenitor cells in tumour vasculogenesis. Pathobiology. 2008;75(5):265鈥?3. CrossRef
11. Ahn JB, Rha SY, Shin SJ, Jeung HC, Kim TS, Zhang X, et al. Circulating endothelial progenitor cells (EPC) for tumor vasculogenesis in gastric cancer patients. Cancer Lett. 2010;288(1):124鈥?2. CrossRef
12. Moschetta M, Mishima Y, Sahin I, Manier S, Glavey S, Vacca A, et al. Role of endothelial progenitor cells in cancer progression. Biochim Biophys Acta. 2014;1846(1):26鈥?9.
13. Roncalli JG, Tongers J, Renault MA, Losordo DW. Endothelial progenitor cells in regenerative medicine and cancer: a decade of research. Trends Biotechnol. 2008;26(5):276鈥?3. CrossRef
14. Dome B, Timar J, Ladanyi A, Paku S, Renyi-Vamos F, Klepetko W, et al. Circulating endothelial cells, bone marrow-derived endothelial progenitor cells and proangiogenic hematopoietic cells in cancer: from biology to therapy. Crit Rev Oncol Hematol. 2009;69(2):108鈥?4. CrossRef
15. Le Bourhis X, Romon R, Hondermarck H. Role of endothelial progenitor cells in breast cancer angiogenesis: from fundamental research to clinical ramifications. Breast Cancer Res Treat. 2010;120(1):17鈥?4. CrossRef
16. Burger PE, Coetzee S, McKeehan WL, Kan M, Cook P, Fan Y, et al. Fibroblast growth factor receptor-1 is expressed by endothelial progenitor cells. Blood. 2002;100(10):3527鈥?5. CrossRef
17. Heissig B, Werb Z, Rafii S, Hattori K. Role of c-kit/Kit ligand signaling in regulating vasculogenesis. Thromb Haemost. 2003;90(4):570鈥?.
18. Fadini GP, Losordo D, Dimmeler S. Critical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use. Circ Res. 2012;110(4):624鈥?7. CrossRef
19. Ho JW, Pang RW, Lau C, Sun CK, Yu WC, Fan ST, et al. Significance of circulating endothelial progenitor cells in hepatocellular carcinoma. Hepatology. 2006;44(4):836鈥?3. CrossRef
20. Zheng PP, Hop WC, Luider TM, Sillevis Smitt PA, Kros JM. Increased levels of circulating endothelial progenitor cells and circulating endothelial nitric oxide synthase in patients with gliomas. Ann Neurol. 2007;62(1):40鈥?. CrossRef
21. Sieghart W, Fellner S, Reiberger T, Ulbrich G, Ferlitsch A, Wacheck V, et al. Differential role of circulating endothelial progenitor cells in cirrhotic patients with or without hepatocellular carcinoma. Dig Liver Dis. 2009;41(12):902鈥?. CrossRef
22. Nowak K, Rafat N, Belle S, Weiss C, Hanusch C, Hohenberger P, et al. Circulating endothelial progenitor cells are increased in human lung cancer and correlate with stage of disease. Eur J Cardiothorac Surg. 2010;37(4):758鈥?3. CrossRef
23. Wognum AW, Eaves AC, Thomas TE. Identification and isolation of hematopoietic stem cells. Arch Med Res. 2003;34(6):461鈥?5. CrossRef
24. Mizrak D, Brittan M, Alison M. CD133: molecule of the moment. J Pathol. 2008;214(1):3鈥?. CrossRef
25. Timmermans F, Van Hauwermeiren F, De Smedt M, Raedt R, Plasschaert F, De Buyzere ML, et al. Endothelial outgrowth cells are not derived from CD133+ cells or CD45+ hematopoietic precursors. Arterioscler Thromb Vasc Biol. 2007;27(7):1572鈥?. CrossRef
26. Case J, Mead LE, Bessler WK, Prater D, White HA, Saadatzadeh MR, et al. Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp Hematol. 2007;35(7):1109鈥?8. CrossRef
27. Prater DN, Case J, Ingram DA, Yoder MC. Working hypothesis to redefine endothelial progenitor cells. Leukemia. 2007;21(6):1141鈥?. CrossRef
28. Timmermans F, Plum J, Yoder MC, Ingram DA, Vandekerckhove B, Case J. Endothelial progenitor cells: identity defined? J Cell Mol Med. 2009;13(1):87鈥?02. CrossRef
29. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003;348(7):593鈥?00. CrossRef
30. Hur J, Yoon CH, Kim HS, Choi JH, Kang HJ, Hwang KK, et al. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol. 2004;24(2):288鈥?3. CrossRef
31. Ingram DA, Mead LE, Tanaka H, Meade V, Fenoglio A, Mortell K, et al. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood. 2004;104(9):2752鈥?0. CrossRef
32. Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, Li F, et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood. 2007;109(5):1801鈥?. CrossRef
33. Medina RJ, O鈥橬eill CL, Sweeney M, Guduric-Fuchs J, Gardiner TA, Simpson DA, et al. Molecular analysis of endothelial progenitor cell (EPC) subtypes reveals two distinct cell populations with different identities. BMC Med Genomics. 2010;3:18. CrossRef
34. Folkman J, Shing Y. Angiogenesis. J Biol Chem. 1992;267(16):10931鈥?.
35. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol. 1992;3(2):65鈥?1.
36. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med. 2001;7(11):1194鈥?01. CrossRef
37. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science. 2003;300(5622):1155鈥?. CrossRef
38. Goon PK, Lip GY, Boos CJ, Stonelake PS, Blann AD. Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. Neoplasia. 2006;8(2):79鈥?8. CrossRef
39. Machein MR, Renninger S, de Lima-Hahn E, Plate KH. Minor contribution of bone marrow-derived endothelial progenitors to the vascularization of murine gliomas. Brain Pathol. 2003;13(4):582鈥?7. CrossRef
40. De Palma M, Venneri MA, Roca C, Naldini L. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med. 2003;9(6):789鈥?5. CrossRef
41. Gothert JR, Gustin SE, van Eekelen JA, Schmidt U, Hall MA, Jane SM, et al. Genetically tagging endothelial cells in vivo: bone marrow-derived cells do not contribute to tumor endothelium. Blood. 2004;104(6):1769鈥?7. CrossRef
42. Peters BA, Diaz LA, Polyak K, Meszler L, Romans K, Guinan EC, et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med. 2005;11(3):261鈥?. CrossRef
43. Asahara T, Kawamoto A, Masuda H. Concise review: circulating endothelial progenitor cells for vascular medicine. Stem Cells. 2011;29(11):1650鈥?. CrossRef
44. Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K, Mittal V. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science. 2008;319(5860):195鈥?. CrossRef
45. Zhao Y, Yu P, Wu R, Ge Y, Wu J, Zhu J, et al. Renal cell carcinoma-adjacent tissues enhance mobilization and recruitment of endothelial progenitor cells to promote the invasion of the neoplasm. Biomed Pharmacother. 2013;67(7):643鈥?. CrossRef
46. Yu P, Ge YZ, Zhao Y, Wu JP, Wu R, Zhou LH, et al. Identification and significance of mobilized endothelial progenitor cells in tumor neovascularization of renal cell carcinoma. Tumour Biol. 2014;35(9):9331鈥?1. CrossRef
47. Uzzan B, Nicolas P, Cucherat M, Perret GY. Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res. 2004;64(9):2941鈥?5. CrossRef
48. Trivella M, Pezzella F, Pastorino U, Harris AL, Altman DG. Microvessel density as a prognostic factor in non-small-cell lung carcinoma: a meta-analysis of individual patient data. Lancet Oncol. 2007;8(6):488鈥?9. CrossRef
49. Zhao SF, Yang XD, Lu MX, Sun GW, Wang YX, Zhang YK, et al. Prognostic significance of VEGF immunohistochemical expression in oral cancer: a meta-analysis of the literature. Tumour Biol. 2013;34(5):3165鈥?1. CrossRef
50. Peng L, Zhan P, Zhou Y, Fang W, Zhao P, Zheng Y, et al. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis. Mol Biol Rep. 2012;39(10):9473鈥?4. CrossRef
51. Kim HK, Song KS, Kim HO, Chung JH, Lee KR, Lee YJ, et al. Circulating numbers of endothelial progenitor cells in patients with gastric and breast cancer. Cancer Lett. 2003;198(1):83鈥?. CrossRef
52. Dome B, Timar J, Dobos J, Meszaros L, Raso E, Paku S, et al. Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer. Cancer Res. 2006;66(14):7341鈥?. CrossRef
53. Bogos K, Renyi-Vamos F, Dobos J, Kenessey I, Tovari J, Timar J, et al. High VEGFR-3-positive circulating lymphatic/vascular endothelial progenitor cell level is associated with poor prognosis in human small cell lung cancer. Clin Cancer Res. 2009;15(5):1741鈥?. CrossRef
54. Pirro M, Cagini L, Paciullo F, Pecoriello R, Mannarino MR, Bagaglia F, et al. Baseline and post-surgery endothelial progenitor cell levels in patients with early-stage non-small-cell lung carcinoma: impact on cancer recurrence and survival. Eur J Cardiothorac Surg. 2013;44(4):e245鈥?2. CrossRef
55. Rafat N, Beck G, Schulte J, Tuettenberg J, Vajkoczy P. Circulating endothelial progenitor cells in malignant gliomas. J Neurosurg. 2010;112(1):43鈥?. CrossRef
56. Corsini E, Ciusani E, Gaviani P, Silvani A, Canazza A, Bernardi G, et al. Decrease in circulating endothelial progenitor cells in treated glioma patients. J Neurooncol. 2012;108(1):123鈥?. CrossRef
57. Yu D, Sun X, Qiu Y, Zhou J, Wu Y, Zhuang L, et al. Identification and clinical significance of mobilized endothelial progenitor cells in tumor vasculogenesis of hepatocellular carcinoma. Clin Cancer Res. 2007;13(13):3814鈥?4. CrossRef
58. Richter-Ehrenstein C, Rentzsch J, Runkel S, Schneider A, Schonfelder G. Endothelial progenitor cells in breast cancer patients. Breast Cancer Res Treat. 2007;106(3):343鈥?. CrossRef
59. Goon PK, Lip GY, Stonelake PS, Blann AD. Circulating endothelial cells and circulating progenitor cells in breast cancer: relationship to endothelial damage/dysfunction/apoptosis, clinicopathologic factors, and the Nottingham Prognostic Index. Neoplasia. 2009;11(8):771鈥?.
60. Brunner M, Thurnher D, Heiduschka G, Grasl M, Brostjan C, Erovic BM. Elevated levels of circulating endothelial progenitor cells in head and neck cancer patients. J Surg Oncol. 2008;98(7):545鈥?0. CrossRef
61. Su Y, Zheng L, Wang Q, Li W, Cai Z, Xiong S, et al. Quantity and clinical relevance of circulating endothelial progenitor cells in human ovarian cancer. J Exp Clin Cancer Res. 2010;29:27. CrossRef
62. Qiu H, Cao L, Wang D, Xu H, Liang Z. High levels of circulating CD34+/VEGFR3+ lymphatic/vascular endothelial progenitor cells is correlated with lymph node metastasis in patients with epithelial ovarian cancer. J Obstet Gynaecol Res. 2013;39(7):1268鈥?5. CrossRef
63. Kim YB, Chung YW, Bae HS, Lee JK, Lee NW, Lee KW, et al. Circulating endothelial progenitor cells in gynaecological cancer. J Int Med Res. 2013;41(2):293鈥?. CrossRef
64. Ramcharan SK, Lip GY, Stonelake PS, Blann AD. Angiogenin outperforms VEGF, EPCs and CECs in predicting Dukes鈥?and AJCC stage in colorectal cancer. Eur J Clin Invest. 2013;43(8):801鈥?. CrossRef
65. Blann AD, Balakrishnan B, Shantsila E, Ryan P, Lip GY. Endothelial progenitor cells and circulating endothelial cells in early prostate cancer: a comparison with plasma vascular markers. Prostate. 2011;71(10):1047鈥?3. CrossRef
66. Bhatt RS, Zurita AJ, O鈥橬eill A, Norden-Zfoni A, Zhang L, Wu HK, et al. Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma. Br J Cancer. 2011;105(1):112鈥?. CrossRef
67. Yang B, Gu W, Peng B, Xu Y, Liu M, Che J, et al. High level of circulating endothelial progenitor cells positively correlates with serum vascular endothelial growth factor in patients with renal cell carcinoma. J Urol. 2012;188(6):2055鈥?1. CrossRef
68. DuBois SG, Stempak D, Wu B, Mokhtari RB, Nayar R, Janeway KA, et al. Circulating endothelial cells and circulating endothelial precursor cells in patients with osteosarcoma. Pediatr Blood Cancer. 2012;58(2):181鈥?. CrossRef
69. Bhaskar A, Gupta R, Kumar L, Sharma A, Sharma MC, Kalaivani M, et al. Circulating endothelial progenitor cells as potential prognostic biomarker in multiple myeloma. Leuk Lymphoma. 2012;53(4):635鈥?0. CrossRef
70. Umemura T, Higashi Y. Endothelial progenitor cells: therapeutic target for cardiovascular diseases. J Pharmacol Sci. 2008;108(1):1鈥?. CrossRef
71. Mayr M, Niederseer D, Niebauer J. From bench to bedside: what physicians need to know about endothelial progenitor cells. Am J Med. 2011;124(6):489鈥?7. CrossRef
72. Naik RP, Jin D, Chuang E, Gold EG, Tousimis EA, Moore AL, et al. Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer. Breast Cancer Res Treat. 2008;107(1):133鈥?. CrossRef
73. Maeda R, Ishii G, Ito M, Hishida T, Yoshida J, Nishimura M, et al. Number of circulating endothelial progenitor cells and intratumoral microvessel density in non-small cell lung cancer patients: differences in angiogenic status between adenocarcinoma histologic subtypes. J Thorac Oncol. 2012;7(3):503鈥?1. CrossRef
74. Ha X, Zhao M, Zhao H, Peng J, Deng Z, Dong J, et al. Identification and clinical significance of circulating endothelial progenitor cells in gastric cancer. Biomarkers. 2013;18(6):487鈥?2. CrossRef
75. Roodhart JM, Langenberg MH, Vermaat JS, Lolkema MP, Baars A, Giles RH, et al. Late release of circulating endothelial cells and endothelial progenitor cells after chemotherapy predicts response and survival in cancer patients. Neoplasia. 2010;12(1):87鈥?4.
76. Sakamori Y, Masago K, Ohmori K, Togashi Y, Nagai H, Okuda C, et al. Increase in circulating endothelial progenitor cells predicts response in patients with advanced non-small-cell lung cancer. Cancer Sci. 2012;103(6):1065鈥?0. CrossRef
77. Massard C, Borget I, Le Deley MC, Taylor M, Gomez-Roca C, Soria JC, et al. Prognostic value of circulating VEGFR2+ bone marrow-derived progenitor cells in patients with advanced cancer. Eur J Cancer. 2012;48(9):1354鈥?2. CrossRef
78. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228鈥?7. CrossRef
79. Pohl M, Werner N, Munding J, Tannapfel A, Graeven U, Nickenig G, et al. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature. Z Gastroenterol. 2011;49(10):1398鈥?06. CrossRef
80. Condon ET, Wang JH, Redmond HP. Surgical injury induces the mobilization of endothelial progenitor cells. Surgery. 2004;135(6):657鈥?1. CrossRef - 作者单位：Yu-Zheng Ge (1)
Ran Wu (1)
Tian-Ze Lu (1)
Hui Xin (1)
Peng Yu (2)
Yan Zhao (3)
Hao Liu (4)
Zheng Xu (1)
Lu-Wei Xu (1)
Jiang-Wei Shen (1)
Xiao Xu (5)
Liu-Hua Zhou (1)
Wen-Cheng Li (1)
Jia-Geng Zhu (1)
Rui-Peng Jia (1)
1. Department of Urology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, 210006, China
2. Department of Urology, The First Hospital of Nanchang, Nanchang University, 128 Xiangshan North Road, Nanchang, 330008, China
3. Department of Urology, Xuzhou Third People鈥檚 Hospital, Jiangsu University, 131 Huancheng Road, Xuzhou, 221005, China
4. Department of Urology, The Second Affiliated Hospital of Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou, 310009, China
5. Department of Radiation Oncology, JiangSu Armed Police General Hospital, 8 Jiangdu South Road, Yangzhou, 225003, China - ISSN：1559-131X
文摘
Human cancers are endowed with sustained vascularization capability, and their growth, invasion, and metastasis are vascularization dependent. Recently, accumulated body of evidence suggests that endothelial progenitor cells (EPCs) can support vasculogenesis and induce angiogenesis through paracrine mechanisms. In addition, numerous clinical studies have revealed the increase in the number of EPCs in the peripheral blood of cancer patients and demonstrated the correlation of circulating EPCs (CEPCs) with the clinical outcomes. This review highlights current enrichment procedures and methods for the detection of CEPCs and different biomarkers to identify CEPCs as well as the functions of EPCs in tumor vascularization. Furthermore, we systematically review available studies on the clinical relevance of CEPCs in cancer patients to explore the potential diagnostic and prognostic values of CEPCs. Although several contrasting results exist, CEPCs can conceivably serve as a promising biomarker for the early diagnosis, prognosis prediction, and treatment response indication in the future. Additionally, further well-designed clinical studies with larger sample size and unique, specific enumeration procedures are warranted to achieve further insight into the clinical implications of CEPCs.